Pfizer Inc. (NYSE:PFE) Shares Purchased by Abner Herrman & Brock LLC

Abner Herrman & Brock LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.3% in the fourth quarter, HoldingsChannel reports. The firm owned 14,750 shares of the biopharmaceutical company’s stock after acquiring an additional 1,000 shares during the period. Abner Herrman & Brock LLC’s holdings in Pfizer were worth $391,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the third quarter valued at $35,000. Finally, Joseph Group Capital Management boosted its stake in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PFE. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $26.51 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a fifty day moving average of $26.27 and a 200-day moving average of $27.86. The company has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.